Surface Oncology Pauses CD39 Program, Slashes Workforce by 20%

cafead

Administrator
Staff member
  • cafead   Nov 02, 2022 at 10:52: PM
via Massachusetts-based Surface Oncology will pause the development of its CD39-targeted antibody SRF617 and cut around 20% of its workforce to focus on its lead anti-IL-27 program SRF388, the company announced Wednesday.

article source
 

<